USD 0.65
(-9.08%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 5.98 Million USD | -38.02% |
2022 | 9.65 Million USD | 143.63% |
2021 | 3.96 Million USD | 57.7% |
2020 | 2.51 Million USD | -3.23% |
2019 | 2.59 Million USD | 47.14% |
2018 | 1.76 Million USD | 34.63% |
2017 | 1.31 Million USD | 333.69% |
2016 | -561 Thousand USD | 34.39% |
2015 | -855 Thousand USD | 61.54% |
2014 | -2.22 Million USD | 83.61% |
2013 | -13.56 Million USD | 0.0% |
2012 | - USD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q2 | 2.75 Million USD | 13.32% |
2024 Q1 | 2.43 Million USD | 1742.42% |
2023 FY | 5.98 Million USD | -38.02% |
2023 Q3 | 610 Thousand USD | -70.59% |
2023 Q2 | 2.07 Million USD | -34.53% |
2023 Q4 | 132 Thousand USD | -78.36% |
2023 Q1 | 3.16 Million USD | 15.96% |
2022 Q4 | 2.73 Million USD | 51.78% |
2022 Q3 | 1.8 Million USD | 58.17% |
2022 Q2 | 1.13 Million USD | -71.44% |
2022 Q1 | 3.98 Million USD | 627.19% |
2022 FY | 9.65 Million USD | 143.63% |
2021 FY | 3.96 Million USD | 57.7% |
2021 Q1 | 1.08 Million USD | 96.9% |
2021 Q2 | 1.5 Million USD | 39.5% |
2021 Q3 | 826 Thousand USD | -45.23% |
2021 Q4 | 548 Thousand USD | -33.66% |
2020 FY | 2.51 Million USD | -3.23% |
2020 Q1 | 779 Thousand USD | -7.26% |
2020 Q2 | 636 Thousand USD | -18.36% |
2020 Q4 | 549 Thousand USD | 0.0% |
2020 Q3 | 549 Thousand USD | -13.68% |
2019 Q2 | 326 Thousand USD | -41.58% |
2019 Q4 | 840 Thousand USD | -3.78% |
2019 FY | 2.59 Million USD | 47.14% |
2019 Q1 | 558 Thousand USD | 150.22% |
2019 Q3 | 873 Thousand USD | 167.79% |
2018 Q4 | 223 Thousand USD | -52.35% |
2018 Q2 | 522 Thousand USD | -5.43% |
2018 Q1 | 552 Thousand USD | -2.99% |
2018 FY | 1.76 Million USD | 34.63% |
2018 Q3 | 468 Thousand USD | -10.34% |
2017 FY | 1.31 Million USD | 333.69% |
2017 Q4 | 569 Thousand USD | 106.16% |
2017 Q3 | 276 Thousand USD | -23.33% |
2017 Q2 | 360 Thousand USD | 239.62% |
2017 Q1 | 106 Thousand USD | 128.04% |
2016 FY | -561 Thousand USD | 34.39% |
2016 Q1 | -102 Thousand USD | 60.62% |
2016 Q2 | -157 Thousand USD | -53.92% |
2016 Q3 | 76 Thousand USD | 148.41% |
2016 Q4 | -378 Thousand USD | -597.37% |
2015 Q4 | -259 Thousand USD | -97.71% |
2015 Q2 | -235 Thousand USD | -2.17% |
2015 Q1 | -230 Thousand USD | 62.42% |
2015 FY | -855 Thousand USD | 61.54% |
2015 Q3 | -131 Thousand USD | 44.26% |
2014 Q3 | -585 Thousand USD | 3.31% |
2014 Q4 | -612 Thousand USD | -4.62% |
2014 Q2 | -605 Thousand USD | 77.32% |
2014 Q1 | -2.66 Million USD | -1151.06% |
2014 FY | -2.22 Million USD | 83.61% |
2013 Q1 | -3.07 Million USD | 0.0% |
2013 Q2 | -3.59 Million USD | -16.9% |
2013 Q4 | -213.26 Thousand USD | 93.42% |
2013 Q3 | -3.23 Million USD | 9.94% |
2013 FY | -13.56 Million USD | 0.0% |
2012 Q2 | - USD | 0.0% |
2012 Q4 | - USD | 0.0% |
2012 FY | - USD | 0.0% |
2012 Q1 | - USD | 0.0% |
2012 Q3 | - USD | 0.0% |
2001 Q2 | 1.5 Million USD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
Bionano Genomics, Inc. | 9.56 Million USD | 37.445% |
Prenetics Global Limited | 8.82 Million USD | 32.23% |
Star Equity Holdings, Inc. | 11.92 Million USD | 49.824% |
CareDx, Inc | 178.32 Million USD | 96.644% |
Exact Sciences Corporation | 1.84 Billion USD | 99.676% |
Exagen Inc. | 29.45 Million USD | 79.685% |
Inotiv, Inc. | 165.44 Million USD | 96.383% |
Guardant Health, Inc. | 336.89 Million USD | 98.224% |
Biodesix, Inc. | 36.07 Million USD | 83.413% |
BioNexus Gene Lab Corp. | 1.32 Million USD | -350.095% |
Precipio, Inc. | 6.01 Million USD | 0.565% |
iSpecimen Inc. | 5.1 Million USD | -17.151% |
Natera, Inc. | 492.74 Million USD | 98.786% |
Aspira Women's Health Inc. | 5.26 Million USD | -13.721% |
Standard BioTools Inc. | 50.45 Million USD | 88.139% |
23andMe Holding Co. | 99.37 Million USD | 93.978% |
Castle Biosciences, Inc. | 174.8 Million USD | 96.577% |
Personalis, Inc. | 18.2 Million USD | 67.135% |
Aclaris Therapeutics, Inc. | 13.16 Million USD | 54.557% |
Applied DNA Sciences, Inc. | 5.53 Million USD | -8.143% |
OpGen, Inc. | -90.69 Thousand USD | 6698.011% |
T2 Biosystems, Inc. | -8.17 Million USD | 173.244% |
Myriad Genetics, Inc. | 476.4 Million USD | 98.744% |
ICON Public Limited Company | 1.81 Billion USD | 99.67% |
NeoGenomics, Inc. | 244.6 Million USD | 97.554% |
Star Equity Holdings, Inc. | 11.92 Million USD | 49.824% |
IDEXX Laboratories, Inc. | 2.18 Billion USD | 99.727% |
RadNet, Inc. | 93 Million USD | 93.566% |
MDxHealth SA | 43.92 Million USD | 86.378% |
Psychemedics Corporation | 8.41 Million USD | 28.872% |
Illumina, Inc. | 2.74 Billion USD | 99.782% |
Check-Cap Ltd. | -212 Thousand USD | 2922.642% |
Twist Bioscience Corporation | 133.34 Million USD | 95.513% |
Fulgent Genetics, Inc. | 104.45 Million USD | 94.271% |
Sera Prognostics, Inc. | 96 Thousand USD | -6133.333% |
ENDRA Life Sciences Inc. | -275.45 Thousand USD | 2272.437% |
OPKO Health, Inc. | 318.12 Million USD | 98.119% |
Medpace Holdings, Inc. | 524.5 Million USD | 98.859% |
Neogen Corporation | 463.9 Million USD | 98.71% |
Intelligent Bio Solutions Inc. | 1.42 Million USD | -319.745% |
Prenetics Global Limited | 8.82 Million USD | 32.23% |
Mainz Biomed B.V. | 509.65 Thousand USD | -1074.118% |
bioAffinity Technologies, Inc. | 791.61 Thousand USD | -655.923% |
Trinity Biotech plc | 19.45 Million USD | 69.234% |
Neuronetics, Inc. | 51.7 Million USD | 88.427% |
Sotera Health Company | 577.15 Million USD | 98.963% |
bioAffinity Technologies, Inc. | 791.61 Thousand USD | -655.923% |